相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study
Thibaud Damy et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy Further Analyses From ATTR-ACT
Claudio Rapezzi et al.
JACC-HEART FAILURE (2021)
Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis
Maria Beatrice Musumeci et al.
JACC-CARDIOVASCULAR IMAGING (2020)
Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis
Virginia S. Hahn et al.
JACC-HEART FAILURE (2020)
Real-world versus trial patients with transthyretin amyloid cardiomyopathy
Marco Canepa et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis
Mathew S. Maurer et al.
CIRCULATION-HEART FAILURE (2019)
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis
Paolo Milani et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging
Sharmila Dorbala et al.
JOURNAL OF CARDIAC FAILURE (2019)
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization
Sharmila Dorbala et al.
JOURNAL OF CARDIAC FAILURE (2019)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Julian D. Gillmore et al.
CIRCULATION (2016)
Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System
Martha Grogan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
Esther Gonzalez-Lopez et al.
EUROPEAN HEART JOURNAL (2015)
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?
Bo-Goran Ericzon et al.
TRANSPLANTATION (2015)
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective
Claudio Rapezzi et al.
EUROPEAN HEART JOURNAL (2013)
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Teresa Coelho et al.
JOURNAL OF NEUROLOGY (2013)
分享论文
